Introduction
Science, technology and production are critical factors required for social and economic development which are especially interwoven in the industrialized countries' economies but weakly linked in the developing ones (SAGASTI, 2004) . Using the numbers of papers and patents as proxies for scientific and technological production, Bernardes and Albuquerque (2003) classified countries into three groups: I, the least developed countries where the connections between science and technology are immature; II, the developing countries where an initial interaction between these sectors has already contributed to development; and III, the industrialized countries. This classification reflects the emergence of fast growing developing economies such as the "BRICs" (O'NEILL et al., 2005) and of the Innovative Developing Countries, IDCs, , those countries with rapidly growing capabilities for undertaking health innovation. This phenomenon challenges the traditional vision of a bipolar world composed of rich countries (the "North)" and the underdeveloped world (the "South") (MOREL, 2003; REUVENY; THOMPSON, 2008) and opens up a rich research agenda to address the characteristics, organization, strategy and evolution of systems of innovation and development (LUNDVALL, 1992; NELSON, 1993; LASTRES;  CASSIOLATO; ARROIO, 2005; ETZKOWITZ, 2008) . and Mahoney et al. (2007) proposed six components, or determinants, of health innovation, which are: (1) R&D i.e. laboratory and clinical studies; (2) regulations for ensuring safety and efficacy; (3) manufacturing capabilities to meet international quality standards; (4) authoritative IP management and licensing; (5) delivery of immunization services by national public and private sectors; and (6) international procurement and trade. In addition there are two other essential elements for success -dynamic linkage and partnerships. Those countries wishing to improve their innovation capabilities must make coordinated, dynamic progress in all six determinants.
The struggle of the developing countries to link science and technology in order to stimulate innovation and achieve industrial and technological 'catch-up' has a parallel in industrialized countries: the difficulties they face to convert, through translational research, biomedical discoveries into practical riches from which humanity can benefit (ANONYMOUS, 2008) . In other words, facing the Sisyphus Challenge of the 21st Century (SAGASTI, 2004 ) can be as difficult as crossing the 'Valley of Death' (BUTLER, 2007 (BUTLER, , 2008 . This raises the interesting possibility that similar strategies and mechanisms could be designed to serve both developing and industrialized countries in addressing their needs in expertise, infrastructure and incentives (TO THWART…, 2008) . They would need to address similar hurdles and obstacles at least four levels: (i) different cultures and motivations of "star" scientists doing basic research (Mode I of knowledge production) as compared to "pasteur" scientists carrying out strategic or applied research or to experts working on technological development including clinical trials, regulation and production (Mode II of knowledge production) (STOKES, 1997; GIBBONS et al., 1994; BABA; SHICHIJO; SEDITA, 2009) ; (ii) differences in infrastructure, policies and governance required for basic research as compared to technological development and production (PAOLI, 2009); (iii) the changing nature of scientific enterprise in which advances require an ever-increasing number of contributors (BARABASI, 2005; GUIMERA et al., 2005) ; (iv)financing issues in translational health research, due to the fundamental role of the public sector in health innovation (ALBUQUERQUE; CASSIOLATO, 2002) , the high costs of taking a discovery to its first clinical trials and then all the way on to drug or vaccine development and manufacturing (DI MASI; HANSEN; GRABOWSKI, 2003) . This paper addresses the organizational infrastructure needed for stimulating innovation and technological development, two critical components of translational health research. This issue has been studied from five different angles e.g.: (1) Our analysis focused on how leading academic institutions have organized their scientific and technological 'spaces' to cope with the challenges of translational research: how they have structured their research laboratories and facilities, how these structures operate internally and how they interact with external partners such as the industrial sector to improve the exploitation of research results and foster economic development. Three basic, increasingly complex prototypes of infrastructure/organizational arrangements could be identified: multiuser equipments, core-facilities and technological platforms. These are the building blocks of higher level arrangements such as technological agglomerations and innovation networks.
Finally we used this lens to analyze the recent evolution and strategic development plans of a leading Latin American public health institution, the Oswaldo Cruz Foundation (Fiocruz, http://www.fiocruz.br), an organization closely linked to Brazil's Ministry of Health and that played a key role during "The Beginnings of Brazilian Science" (STEPAN, 1976) .
The paper has five sections in addition to this introduction. The second one deals with the interaction between science and technology with a focus on health innovation and developing countries, while the third one presents the institutions included in this study, the methodology adopted to analyse their translational research facilities and our main findings. In the fourth section the conceptual framework derived from this analysis is described. The fifth section describes the evolution of translational research at Fiocruz and how this framework shaped the present institutional strategy in health innovation and stimulated the development of a webbased system for the management of its network of technological platforms. The sixth section is the conclusion.
Science, technology and health innovation

Introduction
The economic impact of science and the importance of supporting academic research has been recognized since the end of World War II (BUSH, 1945; NARIN; HAMILTON; OLIVASTRO, 1997 ) and seems to be particularly important in the chemical and pharmaceutical industries (PAVITT, 1991) and the health sector (NELSON, 1995; GELIJNS; ROSENBERG, 1995 
What is health innovation?
Innovation dynamics in the health sector have various distinctive characteristics, especially in regard to the key importance of universities and academic research in biomedical innovations (ALBUQUERQUE; CASSIOLATO, 2002) and of service providers, patients and policy makers for health service innovation (WINDRUM; GARCÍA-GOÑI, 2008) . The importance of technological and social innovation for global health was pointed out by (GARDNER; ACHARYA; YACH, 2007) and the need to incorporate innovation from the political, social, economic, and scientific realms was stressed by (JASSAL; BISHAI, 2009) in order to control diseases such as drugresistant tuberculosis.
We have adopted two basic concepts in this paper: (i) the Health Economic-Industrial Complex (HEIC) of Gadelha that puts health questions within the context of national development and industrial policy (GADELHA, 2006) and (ii) the Global Health Innovation System (GHIS) framework of Mahoney and Morel that shows how countries at different stages of development can address the three types of health "failures" -science failures, market failures and public health failures (MAHONEY; MOREL, 2006b MOREL, , 2006a . Using these lenses we focus on biomedical innovations and organizational strategies for translational health research. When the traditional view of a bipolar, "North"/"South" world prevailed, it was generally accepted that research, development and deployment of health interventions to cope with the diseases of poor countries was mainly a responsibility of the "North". This framework works for Type I / global diseases due to market forces but fails when dealing with Types II-III / neglected-most neglected diseases (TROUILLER et al., 2002; VANDERELST; SPEYBROECK, 2010) . Several approaches and mechanisms have been proposed, or are in operation, to address the need for innovation and new tools to control diseases that affect poor populations 
Health innovation and developing country needs
Results
Relevant information on the above parameters could be found in 164 of the 200 ranked universities (Appendix A). The preferred nomenclature is "Facility" or "Core Facility", used by 82% of the 164 institutions, but other terms are adopted by a few institutions (Figure 1 ). The majority of universities charge for the services provided and allow or stimulate external users, but only a third offer training to new users ( Figure 2 ). 
Classification of translational research facilities
A conceptual and evolutionary framework for the classification of translational research facilities
Large-scale, shared research facilities are not unusual in areas such as high-energy physics and astronomy, due to the high initial investment costs and complexity of instrumentation.
With the advent of modern biotechnology, scientific instrumentation in the life sciences has also become more and more resource-consuming, making sharing research facilities a priority issue (PEERBAYE; MANGEMATIN, 2005) . Our analysis of the top universities described above, visits to selected institutions, a review of the literature and our own observations during the evolution of infrastructure arrangements at Fiocruz (next section) have led us to propose three basic, "evolutionary units" of instrumentation/infrastructure arrangements. The first one is "multi-user equipment" or the initial "cell" or evolutionary step which occurs when an institution decides to buy a single piece of expensive equipment to be used by two or more of their own laboratories. "Facilities" or core facilities or core service facilities (from now on Core Facilities) is the next step and it occurs when the demand for services or instrumentation use grows beyond the capacity of existing infrastructure and new trained personnel is required and hired and new, albeit simple, management rules or arrangements are put in place in order to streamline the function of the unit and to ensure quality control of results from the demanding users, internal or external. The facility is organized and operated to optimize the use of equipment and services (MAYER, 1995) and operates in a demand-driven, passive way, performing the tasks its clients or users are interested in; it requires extra funds, either from the hosting institution or collected through service charges (BUTLER; WILLIAMS, 2002). The third step is "Technological platforms" which in its simplest definition would be a "core facility with a purpose". It is a component of, and participates in a master strategic plan, achieving clear objectives and goals. It provides services to multiple institutions, industry participation being the norm rather than an exception. Our analysis shows that multi-user equipment and core facilities are natural arrangements in academic institutions as their primary goal is to provide support to all ongoing research and development activities carried out by their different laboratories or departments. The nomenclatures 'platform' and 'research platform', however, are adopted by only a minority of universities (8 out of 164; 6 institutions used 'platform' and 2 adopted 'research platform') when referring to their service facilities. We found that this term was used as a synonym of core facility by five institutions while the other three applied this label to designate infrastructure arrangements that are present in technological parks where industry has a strong presence and the priorities are business based goals or on major strategic goals of the parks themselves. The University of Barcelona (UB) represents an interesting case as it runs typical core facilities at its Scientific-Technical Services (http://www.sct.ub.es) but in 1977 also created the Barcelona Science Park, structured on technology platforms that actively participate in research and development projects in collaboration with over 60 companies based at the Park (Parc Científic Barcelona; http://www.pcb.ub.es). module taking into account all subject areas covered by each patent.
Case study: Fiocruz
Introduction
Evolution of Fiocruz organizational strategies
The evolution of the R&D infrastructure of Fiocruz in the last three decades has been remarkable, allowing the institution to become one of the top performing Brazilian institutions in scientific productivity as well as production of public health goods such as vaccines, Technological Development for Public Health) represented a qualitative increase in investments to address growing public health demands due to emerging and re-emerging diseases such as HIV/AIDS and dengue: in the last five years PAPES has invested 7 million US dollars and PDTIS 22 million US dollars. The research laboratories funded by these programs acquired several pieces of high cost, multi-user equipment and as the need came to share them with other research groups some of these laboratories were transformed into full-blown corefacilities providing reliable services to multiple users both inside and outside the institution.
Increased pressure for more services from end users on the one hand, and for more focus, cost-effectiveness and prioritization on public health goals from the Ministry of Health and Center for Technological Development in Health (CDTS) in Rio de Janeiro which will work in close collaboration with industry and the network of technological platforms of the PDTIS/PDTSP Programmes. The facilities and platforms of this technological agglomeration are managed on line by a web-based system located at the CDTS server 6 Discussion "The world would no doubt be a nicer place if the North-South gap disappeared. But it appears unlikely to go away anytime soon." (REUVENY; THOMPSON, 2008) . Sharing research facilities is commonplace in several areas of science and technology and became an important issue in the biological and biomedical sciences with the advent of modern biotechnology. As noted by (PEERBAYE; MANGEMATIN, 2005) , since the development of genomics and tools for 'mass gene and protein exploration', instrumentation has become more and more resource consuming, making sharing research facilities a growing issue and a means to transfer technology.
Our analysis on how the best universities organize, share and manage their research facilities, and our study on the evolution of these arrangements during the last decades in a leading Brazilian biomedical institution, allowed us to propose a typology of increasingly complex, prototype R&D organizational structures: Multi-user equipments, core-facilities and technological platforms. This typology, based on objective criteria (Table I) , should help managers and decision-makers deal with this important component of technology transfer and translational health research, as each category needs specific requirements in terms of financing, technical expertise and strategic management. Transforming a piece of multi-user equipment into a core-facility, for example, requires hiring and training new technical staff in quality management; moving from core-facilities to technological platforms requires profound cultural changes, as it means moving from "first-in, first-out" user attendance to deciding who, or which project, has strategic priority or rights to be served by the platforms. Incomplete or wrong perception about the nature and mission of each type of shared infrastructure arrangement can lead to the implementation of inadequate facilities, user dissatisfaction and institutional conflicts. This The web-based system we developed and implemented to manage Fiocruz core facilities and technological platforms represented a key step and a turning point in this process, as it allowed continuous, interactive contact among all interested parties -decision-makers, managers, technical staff, clients and end users.
Partnerships between public institutions and the industrial sector are a critical component of modern biotechnology as they require innovative management and substantial investments in human resources, laboratory facilities and infrastructure. The typology proposed in this article is both a product and a driver of the long-term strategy of Fiocruz on translational health research. Transitioning from its infrastructure of the 1970s', which was based on multi-user equipments, all the way to the technological agglomeration of the 2010s' (Table II) was a long process that required critical strategic decisions and profound managerial and cultural changes.
The proposed typology and this experience of a developing country institution may prove useful for organizations facing similar transitions and challenges in other countries and regions. 
